Hostname: page-component-cd9895bd7-q99xh Total loading time: 0 Render date: 2024-12-25T16:24:33.035Z Has data issue: false hasContentIssue false
  • English
  • Français

Evolución de los pacientes en la esquizofrenia I: correlatos con variables sociodemográficas, manifestaciones psicopatológicas y efectos secundarios

Published online by Cambridge University Press:  12 May 2020

Alex Hofer ,
Susanne Baumgartner ,
Monika Edlinger ,
Martina Hummer ,
Georg Kemmler ,
Maria A. Rettenbacher ,
Hansjoerg Schweigkofler ,
Josef Schwitzer  and
W. Wolfgang Fleischhacker
Alex Hofer
Affiliation:
Departamento de Psiquiatría Biológica, Universidad Médica de Innsbruck, Anichstrasse 35, A-6020Innsbruck, Austria
Susanne Baumgartner
Affiliation:
Departamento de Psiquiatría Biológica, Universidad Médica de Innsbruck, Anichstrasse 35, A-6020Innsbruck, Austria
Monika Edlinger
Affiliation:
Departamento de Psiquiatría General, Hospital General Bressanone, Bressanone, Italia
Martina Hummer
Affiliation:
Departamento de Psiquiatría Biológica, Universidad Médica de Innsbruck, Anichstrasse 35, A-6020Innsbruck, Austria
Georg Kemmler
Affiliation:
Departamento de Psiquiatría Biológica, Universidad Médica de Innsbruck, Anichstrasse 35, A-6020Innsbruck, Austria
Maria A. Rettenbacher
Affiliation:
Departamento de Psiquiatría Biológica, Universidad Médica de Innsbruck, Anichstrasse 35, A-6020Innsbruck, Austria
Hansjoerg Schweigkofler
Affiliation:
Departamento de Psiquiatría General, Hospital General Bressanone, Bressanone, Italia
Josef Schwitzer
Affiliation:
Departamento de Psiquiatría General, Hospital General Bressanone, Bressanone, Italia
W. Wolfgang Fleischhacker
Affiliation:
Departamento de Psiquiatría Biológica, Universidad Médica de Innsbruck, Anichstrasse 35, A-6020Innsbruck, Austria
Get access

Resumen

Objetivo

El presente estudio transversal examinó las relaciones de las manifestaciones psicopatológicas, los efectos secundarios y los factores sociodemográficos con el resultado del tratamiento desde el punto de vista de la calidad de vida (CdV), el funcionamiento y las necesidades de asistencia de los pacientes.

Métodos

Se estudió a 60 pacientes ambulatorios con esquizofrenia crónica que habían tenido tratamiento con clozapina u olanzapina durante 6 meses al menos.

Resultados

La mayoría de los síntomas psicopatológicos, igual que los efectos secundarios psíquicos, el aumento de peso y el sexo femenino se asociaban con una CdV más baja, mientras que los síntomas cognitivos correlacionaban con una CdV mejor. El sexo femenino, los síntomas cognitivos y el parkinsonismo influían negativamente en el funcionamiento ocupacional, y los síntomas negativos determinaban una menor probabilidad de vida independiente. La edad, el nivel educativo, la depresión/ansiedad, los síntomas negativos y los efectos secundarios psíquicos eran predictores de las necesidades de asistencia de los pacientes.

Conclusión

Nuestros resultados destacan la naturaleza compleja de la evolución del paciente en la esquizofrenia y ponen de nuevo el énfasis en la necesidad de centrarse en la eficacia, es decir, en la mejoría de los síntomas y además la seguridad farmacológica, en estos pacientes.

Keywords

EsquizofreniaEvoluciónNecesidadesCalidad de vidaEmpleo
Type
Artículo Original
Information
European Psychiatry (Ed. Española) , Volume 13 , Issue 2 , March 2006 , pp. 77 - 85
Copyright
Copyright © European Psychiatric Association 2006

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Bibliografía

[1]Addington, J, Addington, DPremorbid functioning, cognitive functioning, symptoms, and outcome in schizophrenia. J Psychiatry Neurosci 1993;18:18–23.Google Scholar
[2]Allison, DB, Mackell, JA, McDonnell, DDThe impact of weight gain on quality of life among persons with schizophrenia. Psychiatr Serv 2003;54:565-7.CrossRefGoogle ScholarPubMed
[3]Beiser, M, Bean, G, Erickson, D, Zhang, J, lacono, WG, Rector, NABiological and psychosocial predictors of job performance following a first episode of psychosis. Am J Psychiatry 1994;151:857-63.Google ScholarPubMed
[4]Breier, A, Sctreiber, JL, Dyer, J, Pickar, DNational Institute of Mental Health longitudinal study of chronic schizophrenia: prognosis and predictors of outcome. Arch Gen Psychiatry 1991;48:239-46.CrossRefGoogle ScholarPubMed
[5]Brekke, JS, Kohrt, B, Green, MENeuropsychological functioning as a moderator of the relationship between psychosocial functioning and the subjective experience of self and life in schizophrenia. Schizophr Bull 2001;27:697–708.CrossRefGoogle Scholar
[6]Browne, S, Roe, M, Lane, A, Gervin, M, Morris, M, Kinsella, A et al. Quality of life in schizophrenia: relationship to sociodemographic factors, symptomatology, and tardive dyskinesia. Acta Psychiatr Scand 1996;94:118-24.CrossRefGoogle ScholarPubMed
[7]DeJong, A, Giel, R, Slooff, CJ, Wiersma, DRelationship between symptomatology and social disability. Empirical evidence from a follow-up study of schizophrenic patients. Soc Psychiatry 1986;21: 200-5.CrossRefGoogle ScholarPubMed
[8]Dickerson, F, Boronow, JJ, Ringel, N, Parente, ESocial functioning and neurocognitive deficits in outpatients with schizophrenia: a 2 - year follow-up. Schizophr Res 1999;37:13–20.CrossRefGoogle ScholarPubMed
[9]Fleischhacker, WWPharmacological treatment of schizophrenia: a review. In: Maj, M, Sartorius, N editors. Schizophrenia. WPA series evidence and experience in psychiatry. Chichester, NY, Weinheim, Brisbane, Singapore, Toronto: Wiley; 2002. p. 75-113.Google Scholar
[10]Fleischhacker, WW, Rabinowitz, J, Kemmler, G, Lasser, RA, Mehnert, APerceiving functioning, well-being and association with psychiatric symptomatology in clinically stable schizophrenia patients treated with loog-acting risperidone for 1 year. Br J Psychiatry 2005; [in press].CrossRefGoogle Scholar
[11]Foldemo, A, Bogren, LNeed assessment and quality of life in outpatients with schizophrenia: a 5-year follow-up study. Scand J Caring Sci 2002;16:393-8.CrossRefGoogle ScholarPubMed
[12]Hofer, A, Kemmler, G, Eder, U, Edlinger, M, Hummer, M, Fleischhacker, WWQuality of life in schizophrenia: the impact of psychopathology, drug attitude and side effects. J Clin Psychiatry 2004;65: 932-9.CrossRefGoogle ScholarPubMed
[13]Hoffmann, K, Priebe, SWelche Beduerfnisse nach Hilfe haben schizophrene Langzeitpatienten? Probleme der Selbst- und Fremdbeurteilung von “Needs”. Fortschr Neurol Psychiat 1996;64:473-81.CrossRefGoogle Scholar
[14]Kallert, TW, Leisse, MBe treuungsbeduerfnisse schizophrener Patienten im Jahr nach Klinikentlassung in der Versorgungsregion Dresden. Fortschr Neurol Psychiat 2000;68:176-87.CrossRefGoogle Scholar
[15]Kay, SR, Fiszbein, A, Opler, LAThe Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull 1987;13:261-76.CrossRefGoogle Scholar
[16]Kemmler, G, Holzner, B, Neudorfer, C, Meise, U, Hinterhuber, HGeneral life satisfaction and domain-specific quality of life in chronic schizophrenic patients. Qual Life Res 1997;6:265-73.CrossRefGoogle ScholarPubMed
[17]Lambert, M, Naber, DCurrent issues in schizophrenia: overview of patient acceptability, functioning capacity and quality of life. CNS Drugs 2004;18(Suppl 2):5–17.CrossRefGoogle ScholarPubMed
[18]Lehman, AF, Goldberg, R, Dixon, LB, McNary, S, Postrado, L, Hackman, A et al. Improving employment outcomes for persons with severe mental illnesses. Arch Gen Psychiatry 2002;59:165-72.CrossRefGoogle ScholarPubMed
[19]Leung, A, Chue, PSex differences in schizophrenia, a review of the literature. Acta Psychiatr Scand 2000;101:3–38.CrossRefGoogle Scholar
[20]Lindenmayer, JP, Bernstein-Hyman, R, Grochowski, SFive-factor raodel of schizophrenia. J Nerv Ment Dis 1994;182:631-8.CrossRefGoogle ScholarPubMed
[21]Lindenmayer, JP, Grochowski, S, Hyman, RBFive factor model of schizophrenia: replication across samples. Schizophr Res 1995; 14: 229-34.CrossRefGoogle ScholarPubMed
[22]Lingjaerde, O, Ahlfors, UG, Bech, P, Dencker, SJ, Elgen, KThe UKU Side Effect Rating Scale—a new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neurolepdc-treatedpatients. Acta Psychiatr Scand Suppl 1987;334:1–100.CrossRefGoogle Scholar
[23]McGurk, S, Moriarty, PJ, Harvey, PD, Parrella, M, White, L, Davis, KLThe longitudinal relationship of clinical symptoms, cognitive functioning, and adaptive life in geriatric schizophrenia. Schizophr Res 2000;42:47–55.CrossRefGoogle ScholarPubMed
[24]McGurk, SR, Mueser, KTCognitive functioning and employment in severe mental illness. J Nerv Ment Dis 2003;191:789-98.CrossRefGoogle ScholarPubMed
[25]Mercier, C, Peladeau, N, Tempier, RAge, gender and quality of life. Community Ment Health J 1998;34:487–500.CrossRefGoogle ScholarPubMed
[26]Mueser, KTCognitive functioning, social adjustment, and long-term outcome in schizophrenia. In: Sharma, T, Harvey, P editors. Cognition in schizophrenia. New York NY: Oxford University Press; 2000. p. 157-77.Google Scholar
[27]Mueser, KTCognitive impairment, symptoms, social functioning, and vocational rehabilitation in schizophrenia. In: Kashima, H, Falloon, IRH, Mizuno, M, Asai, M editors. Comprehensive treatment of schizophrenia: linking neurobehavioral findings to psychosocial approaches. Tokyo: Springer; 2002. p. 344-51.CrossRefGoogle Scholar
[28]Norman, RM, Malla, AKCorrelations over time between dysphoric mood and symptomatology in schizophrenia. Compr Psychiatry 1994;35:34-8.CrossRefGoogle Scholar
[29]Norman, RMG, Malla, AK, McLean, T, Voruganti, LP, Cortese, L, Mclntosh, E et al. The relationship of symptoms and level of functioning in schizophrenia to general wellbeing and the Quality of Life Scale. Acta Psychiatr Scand 2000;102:303-9.CrossRefGoogle ScholarPubMed
[30]Ochoa, S, Haro, JM, Autonell, J, Pendas, A, Teba, F, Marquez, M et al. Met and unmet needs of schizophrenia patients in a Spanish sample. Schizophr Bull 2003;29:201-10.CrossRefGoogle Scholar
[31]Priebe, S, Heinze, M, Jakel, ABerliner Bedurfnis Inventar (BeBI). FU Berlin: Abteilung fbr Sozialpsychiatrie; 1993.Google Scholar
[32]Prudo, R, Monroe Blum, HFive year outcome and prognosis in schizophrenia; a report from the London field centre of the international pilot study of schizophrenia. Br J Psychiatry 1987;150:345-54.CrossRefGoogle ScholarPubMed
[33]Racenstein, JM, Harrow, M, Reed, R, Martin, E, Herbener, E, Penn, DLThe relationship between positive symptoms and instrumental work functioning in schizophrenia: a 10 year follow-up study. Schizophr Res 2002;56:95–103.CrossRefGoogle ScholarPubMed
[34]Sartorius, N, Fleischhacker, WW, Gjerris, U, Kern, U, Knapp, M, Leonhard, BE et al. The usefulness and use of second generation antipsychotic medications—an update. Curr Opin Psychiatry 2003;16(Suppl l):1–44.Google Scholar
[35]Slade, M, Thornicroft, G, Loftus, L et al. CAN: The Camberwell Assessment of Need. London: Gaskell; 1999.Google Scholar
[36]Swartz, MS, Perkins, DO, Stroup, TS, McEvoy, JP, Nieri, JM, Haak, DCAssessing clinical and functional outcomes in the Clinical Antipsychotic Triais of Intervention Effectiveness (CATIE) schizophrenia trial. Schizophr Bull 2003;29:33–43.CrossRefGoogle Scholar
[37]Thornicroft, G, Tansella, M, Becker, T, Knapp, M, Leese, M, Schene, A et al. The personal impact of schizophrenia in Europe. Schizophr Res 2004;69:125-32.CrossRefGoogle ScholarPubMed
[38]The, WHOQOL GroupDevelopment of the World Health Organization WHOQOL-BREF quality of life assessment. Psychol Med 1998;28:551-8.Google Scholar
[39]Voruganti, LNP, Heslegrave, RJ, Awad, AGQuality of life measurement during antipsychotic drug therapy of schizophrenia. J Psychiatr Neurosci 1997;22:267-74.Google ScholarPubMed